266 related articles for article (PubMed ID: 9347665)
1. Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer.
Punyammalee B; Manoromana S; Purisa W; Chariyalertsak S; Rerkamnuaychok B
J Med Assoc Thai; 1997 Sep; 80 Suppl 1():S162-73. PubMed ID: 9347665
[TBL] [Abstract][Full Text] [Related]
2. Biological and clinical significance of concurrent p53 gene alterations, MDR1 gene expression, and S-phase fraction analyses in breast cancer patients treated with primary chemotherapy or radiotherapy.
Chevillard S; Lebeau J; Pouillart P; de Toma C; Beldjord C; Asselain B; Klijanienko J; Fourquet A; Magdelénat H; Vielh P
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2471-8. PubMed ID: 9815649
[TBL] [Abstract][Full Text] [Related]
3. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
[TBL] [Abstract][Full Text] [Related]
4. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells.
Mutoh K; Tsukahara S; Mitsuhashi J; Katayama K; Sugimoto Y
Cancer Sci; 2006 Nov; 97(11):1198-204. PubMed ID: 16925584
[TBL] [Abstract][Full Text] [Related]
5. MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients.
Lizard-Nacol S; Genne P; Coudert B; Riedinger JM; Arnal M; Sancy C; Brunet-Lecomte P; Fargeot P
Anticancer Res; 1999; 19(4C):3575-81. PubMed ID: 10629655
[TBL] [Abstract][Full Text] [Related]
6. MDR1 gene expression in primary and advanced breast cancer.
Yang X; Uziely B; Groshen S; Lukas J; Israel V; Russell C; Dunnington G; Formenti S; Muggia F; Press MF
Lab Invest; 1999 Mar; 79(3):271-80. PubMed ID: 10092063
[TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of expression of multidrug resistance gene in breast cancer tissue].
Liu X; Song S; Shi C
Zhonghua Yi Xue Za Zhi; 1997 Jul; 77(7):488-90. PubMed ID: 9772445
[TBL] [Abstract][Full Text] [Related]
8. Comparison of multidrug resistance gene expression levels with malignant potentials and influence of chemotherapy in urothelial cancers.
Kakehi Y; Wu WJ; Kim WJ; Arao S; Fukumoto M; Yoshida O
Int J Urol; 1995 Nov; 2(5):309-15. PubMed ID: 8749949
[TBL] [Abstract][Full Text] [Related]
9. Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients.
Vaclavikova R; Nordgard SH; Alnaes GI; Hubackova M; Kubala E; Kodet R; Mrhalova M; Novotny J; Gut I; Kristensen VN; Soucek P
Pharmacogenet Genomics; 2008 Mar; 18(3):263-73. PubMed ID: 18300948
[TBL] [Abstract][Full Text] [Related]
10. Semiquantitative RT-PCR evaluation of the MDR1 gene expression in patients with acute myeloid leukemia.
Trnková Z; Bedrlíková R; Marková J; Michalová K; Stöckbauer P; Schwarz J
Neoplasma; 2007; 54(5):383-90. PubMed ID: 17688368
[TBL] [Abstract][Full Text] [Related]
11. Expression of the human multidrug resistance gene (MDR1) and prognostic correlation in human osteogenic sarcoma.
Imanishi T; Abe Y; Suto R; Higaki S; Ueyama Y; Nakamura M; Tamaoki N; Fukuda H; Imai N
Tokai J Exp Clin Med; 1994 Sep; 19(1-2):39-46. PubMed ID: 7660382
[TBL] [Abstract][Full Text] [Related]
12. Clinical relationship between MDR1 gene and gallbladder cancer.
Wang BL; Zhai HY; Chen BY; Zhai SP; Yang HY; Chen XP; Zhao WT; Meng L
Hepatobiliary Pancreat Dis Int; 2004 May; 3(2):296-9. PubMed ID: 15138130
[TBL] [Abstract][Full Text] [Related]
13. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
14. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients.
Taheri M; Mahjoubi F; Omranipour R
Genet Mol Res; 2010 Jan; 9(1):34-40. PubMed ID: 20082268
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible?
Ratnasinghe D; Daschner PJ; Anver MR; Kasprzak BH; Taylor PR; Yeh GC; Tangrea JA
Anticancer Res; 2001; 21(3C):2141-7. PubMed ID: 11501838
[TBL] [Abstract][Full Text] [Related]
16. Immunomagnetic purification of human breast carcinoma cells allows tumor-specific detection of multidrug resistance gene 1-mRNA by reverse transcriptase polymerase chain reaction in fine-needle aspirates.
Maas RA; Bruning PF; Breedijk AJ; Top B; Peterse HL
Lab Invest; 1995 Jun; 72(6):760-4. PubMed ID: 7540237
[TBL] [Abstract][Full Text] [Related]
17. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
18. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
19. Drug resistance in chemotherapy for breast cancer.
Saeki T; Tsuruo T; Sato W; Nishikawsa K
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361
[TBL] [Abstract][Full Text] [Related]
20. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment.
Tada Y; Wada M; Kuroiwa K; Kinugawa N; Harada T; Nagayama J; Nakagawa M; Naito S; Kuwano M
Clin Cancer Res; 2000 Dec; 6(12):4618-27. PubMed ID: 11156211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
